High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
暂无分享,去创建一个
[1] S. Rodenhuis,et al. Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.
[2] G. Kraft,et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. , 2003, Blood.
[3] D. Flockhart,et al. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[4] N. Hellings,et al. Insights into the immunopathogenesis of multiple sclerosis , 2002, Immunologic research.
[5] W. Collard,et al. Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[6] O. Khan,et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy , 2001, Multiple sclerosis.
[7] M. Gobbini,et al. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis , 1999, Journal of Neuroimmunology.
[8] F. Appelbaum,et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.
[9] M. Eichelbaum,et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Appelbaum,et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Degos,et al. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. , 1995, European neurology.
[12] R. Beck,et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.
[13] R. Herndon,et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis , 1993, Neurology.
[14] M. Moore,et al. Rapid development of enhanced clearance after high‐dose cyclophosphamide , 1988, Clinical pharmacology and therapeutics.
[15] J. Kovach,et al. Pharmacokinetics of anticancer agents in humans , 1983 .